What does ARATA do?
ARATA is Japan's second-largest wholesaler of daily necessities, cosmetics, household goods and pet supplies, behind PALTAC. It is the middle layer of distribution: it buys from about 1,100 manufacturers and delivers to roughly 3,370 retailers across the country. Drugstores, home centers and supermarkets are its main customers. ARATA runs as a single business, formed in 2002 by combining three regional wholesalers and expanded since by acquiring more.
ARATA earns a spread. It buys goods in bulk, stores them, delivers them daily through its own temperature-controlled network, and helps stores plan what goes on the shelf. Gross margin is only about 9.7% and operating margin about 1.3%, so it makes a little money on very large volume. Its extra value is data: ARATA analyzes point-of-sale records to design shelf plans, and it carries a growing book of exclusive lines that rivals cannot stock, about 7.8% of sales.
The company grows in three ways. It consolidates a fragmenting wholesale industry by buying smaller rivals. It deepens its data edge — in December 2025 it joined the True Data alliance, a shared purchase-record pool covering about 60 million people. And it has moved upstream: in January 2026 it bought msh, the maker of the Love Liner cosmetics brand, so it now owns product rather than only carrying it.
FY3/26 was the year ARATA crossed ¥1trn of revenue, at ¥1,004.7bn, a 4.1% annual growth rate over three years. But operating profit fell 11.9% to ¥13.2bn, and the company guides FY3/27 lower still, to ¥11.0bn — it calls next year the bottom. Return on capital employed has slipped from 10.4% to 8.2% over three years as the margin thinned. ARATA also carries ¥9.2bn of net debt, the only distributor among its peers not in a net-cash position, and its shares trade at 0.69x book value.
The investment question is whether ARATA is a value opportunity or a squeezed middleman. It earns a 1.3% margin and trades below book at 8.7x forward operating profit — cheap if the bad year passes, a trap if its own customers keep pressing on price. This profile answers that in five steps. It covers how the share price got here, what investors are debating, what is changing in ownership and customers, which disclosures could move the multiple, and what the business is worth.
What has driven the stock over the past two years?
ARATA buys daily necessities, cosmetics and pet goods from about 1,100 makers and delivers them to roughly 3,370 retailers, earning a thin spread on very large volume. Its 2024 climb rode optimism about crossing ¥1trn of revenue; the long slide since reflected a 1.3% margin the market came to read as structural, not a passing dip.
01 · When investors paid up for the ¥1-trillion story ARATA rose to a post-split high of ¥3,685 on September 10, 2024. The 2:1 split that January had widened the float and lowered the entry price, and investors bought the company's approach to ¥1trn of revenue and its record of rolling up smaller wholesalers. Demand for daily necessities looked steady and hard to disrupt. At the peak the enterprise value was roughly ~9x the operating-profit guidance then in force.
02 · When the thin margin came into focus Through 2025 ARATA kept growing sales, but its costs grew faster. Warehouse spending, freight and the center fees retailers charge to stock their shelves all rose, and operating margin drifted toward 1.3%. Investors began to read that 1.3% spread as a structural feature of a wholesaler with little pricing power, not a passing dip, and the shares slid through the year.
03 · The February 2026 guidance cut On February 10, 2026, after the close, ARATA cut its FY3/26 operating-profit guidance by 17.6%. Coming after two years of margin erosion, the cut read as confirmation that cost inflation was permanent rather than temporary. Investors kept selling, and the de-rating continued into the spring.
04 · Where the stock stands now ARATA reported FY3/26 results on May 14 — revenue past ¥1trn but operating profit down 11.9% — and guided FY3/27 as an earnings trough alongside its 2030 medium-term plan. The slide bottomed at ¥2,382 on June 22, 2026, then recovered to ¥2,570 by July 16, 8.7x forward EV/EBIT. Over 24 months ARATA fell 26.6% while TOPIX rose 47.0%, one of the market's worst relative performers. The open question is whether that gap marks a squeezed middleman or a mispriced one.
Live Investor Debates
Three debates explain why a wholesaler that just crossed ¥1trn of revenue trades below book at 8.7x forward EV/EBIT. Each will be tested by disclosures due within the next twelve months.
ARATA sits between about 1,100 makers and 3,370 retailers, buying in bulk, warehousing, and delivering daily on a spread of roughly 1.3%. As drugstore and supermarket chains merge, they gain the scale to run logistics themselves. The debate is whether ARATA's network stays cheaper than doing it in-house.
In FY3/26 ARATA's sales rose 1.9% but its overheads rose 3.6% and freight 5.1%, so operating profit fell and margin slipped to 1.3%. FY3/27 guidance puts it at 1.1%. The debate is whether inflation and one-off costs caused this, or whether retail buyer-power has set a lower ceiling.
In January 2026 ARATA bought msh, maker of the Love Liner eye-makeup brand, adding about ¥8.6bn of goodwill. A distributor was buying a brand it used only to carry. The debate is whether owning the product captures the maker's margin, or stretches ARATA outside what it does well.
What is changing in who owns it, who buys from it, and the edge?
The 2:1 split in January 2024 widened the float and lowered the entry price, opening the register to more investors. ARATA has no controlling parent; its largest holder is a passive trust bank at 11.6%. Next check: any large-holding filing or an activist entry.
Foreign ownership runs near 22%, and it includes Fidelity Low-Priced Stock at 3.29% — a value fund already holding a stock at 0.69x book. The supplier Lion holds 2.79% as a cross-holder. Next check: whether any holder presses for a cross-holding sell-down or a buyback.
Apparent founder-linked holders (Otowa Shokusan 6.28%, Hatanaka 2.67%) sit alongside the trusts, and no single block controls the company. That leaves the door open to change with no blocker in the way. Next check: any move in the founder-linked or Lion stakes.
The drugstore channel is 52% of sales and rising, and Tsuruha is the only account above 10%, at 13.6%. The book is concentrated in the fastest-growing retail format. Next check: whether the drugstore share keeps climbing.
Tsuruha is folding into the Welcia and Aeon orbit, which raises the buyer power of ARATA's single largest account. A bigger customer can press harder on price and on center fees. Next check: whether the Tsuruha account grows or is squeezed on fees.
Selling to about 3,370 retailers across the country spreads the rest of the book, so no other account approaches 10%. That diversification is why one squeezed customer does not break the model. Next check: any second account crossing 10% of sales.
ARATA joined the True Data alliance, a shared purchase-record pool covering about 60 million people, deepening the category data behind its shelf plans. Better data makes its store-front marketing harder to replace. Next check: the exclusive-line and owned-brand share of sales rising.
The msh acquisition moved ARATA upstream into owning the Love Liner cosmetics brand, adding higher-margin product to a thin-spread book. Next check: whether the cosmetics mix lifts the blended gross margin.
ARATA joined the CODE joint-delivery consortium with Kao, PALTAC and Medipal, sharing trucks against driver shortages and fuel costs. Pooling delivery defends the logistics edge as costs rise. Next check: the overhead and logistics cost curve bending down.
Disclosure & Capital Levers
Investors are paying a trough multiple on a trough year. Three disclosures, each with a date attached, will do most of the work of settling whether that is right over the next year and a half.
Scenario Pathways
At ¥2,570 (July 16, 2026), an enterprise value of ~¥95.3bn against FY3/27 operating-profit guidance of ¥11.0bn implies 8.7x forward EV/EBIT. The three scenarios below are JII estimates, not company guidance.
- Center fees and buyer-power hold margin at 1.1% or below.
- The 2030 margin recovery fails to arrive.
- Operating profit stalls near the ¥11.0bn trough.
- Trough OP × 6.5x maps to ¥2,217 per share.
Even here the ¥112 dividend yields 4.4% at the current price, and the payout has risen eleven years running.
- Overhead growth slows below sales growth.
- Exclusive-line and cosmetics mix lifts gross margin.
- Mid-cycle operating profit recovers toward ¥13.0bn.
- ¥13.0bn × 7.8x maps to ¥3,110 per share.
- Recurring profit heads toward the ¥16bn 2030 target.
- A cross-holding unwind plus buyback defends book value.
- Operating profit runs to ¥14.0bn.
- ¥14.0bn × 8.5x maps to ¥3,636 per share.
The top of the range, ¥3,636, sits below the September 2024 peak of ¥3,685 — reclaiming the record would need the FY3/27 trough clearly behind the company.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator (金融商品取引業者) under Japan's Financial Instruments and Exchange Act. JII does not have a 投資助言・代理業 registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion. JII does not have an investment opinion on any security discussed.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Conflicts & positions. JII may provide paid IR diagnostic, translation, or interpretation services to Japanese listed companies, including companies discussed in this publication. JII does not trade in or hold positions in the securities of companies profiled. Where a JII engagement exists with a profiled company, that fact will be disclosed at the top of the profile.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。